Healthcare
Hospitals
from 1,419 today
Q1FY27 was a record quarter with robust volume-driven revenue and EBITDA growth, while the Noida unit's narrowing losses clear a major overhang. We retain a Buy rating with a higher price target of 1683, valuing the stock at 53x 1-year forward P/E.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
